Smederevac/iStock via Getty ImagesALX Oncology Holdings Inc. (NASDAQ:ALXO) develops immuno-oncology treatments to improve the immune response against cancer. The company’s leading product candidate is Evorpacept [ALX148], a first-in-class CD47 inhibitor that blocks cancer cells' “don’t eat me” signal. Unlike standard CD47 inhibitors, Evorpacept has an inactive Fc domain that reduces side effects. ALXO’s pipeline explores diverse combinations of Evorpacept with chemotherapy, targeted agents, and checkpoi ...